{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:38:51Z","timestamp":1761741531177,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.6061\/clinics\/2013(09)03","type":"journal-article","created":{"date-parts":[[2013,9,26]],"date-time":"2013-09-26T09:24:30Z","timestamp":1380187470000},"page":"1189-1196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis"],"prefix":"10.1016","volume":"68","author":[{"given":"Natalia P.","family":"Machado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgard Torres","family":"dos Reis Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Roberta M.P.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele S.","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Porro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rozana M.","family":"Ciconelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo M.","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.6061\/clinics\/2013(09)03_bib1","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.6061\/clinics\/2013(09)03_bib2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.6061\/clinics\/2013(09)03_bib3","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.6061\/clinics\/2013(09)03_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.6061\/clinics\/2013(09)03_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.6061\/clinics\/2013(09)03_bib6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.2010.224154","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"60","author":"Mowat","year":"2011","journal-title":"Gut"},{"issue":"3","key":"10.6061\/clinics\/2013(09)03_bib7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1186\/ar1724","article-title":"Dermatological conditions during TNF-\u03b1-blocking therapy in patients with rheumatoid arthritis: a prospective study","volume":"7","author":"Flendrie","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.6061\/clinics\/2013(09)03_bib8","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1002\/ibd.21643","article-title":"Frequency, Phenotype, Outcome, and Therapeutic Impact of Skin Reactions Following Initiation of Adalimumab Therapy: Experience from a Consecutive Cohort of Inflammatory Bowel Disease Patients","volume":"17","author":"Baumgart","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.6061\/clinics\/2013(09)03_bib9","first-page":"333","article-title":"Lepromatous leprosy associated with the use of anti-TNF \u03b1 therapy: case report","volume":"50","author":"Freitas","year":"2010","journal-title":"Bras J Rheumatol"},{"issue":"15","key":"10.6061\/clinics\/2013(09)03_bib10","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor-alfa neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"7","key":"10.6061\/clinics\/2013(09)03_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"issue":"10","key":"10.6061\/clinics\/2013(09)03_bib12","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1086\/598331","article-title":"Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis","volume":"48","author":"McDonald","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.6061\/clinics\/2013(09)03_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alfa therapy: results from the British Society for Rheumatology Biologics Register","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.6061\/clinics\/2013(09)03_bib14","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1365-2036.2009.03955.x","article-title":"Anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease","volume":"29","author":"Fiorino","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.6061\/clinics\/2013(09)03_bib15","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","article-title":"Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis","volume":"50","author":"Amari","year":"2011","journal-title":"Rheumatology"},{"issue":"3","key":"10.6061\/clinics\/2013(09)03_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.6061\/clinics\/2013(09)03_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.6061\/clinics\/2013(09)03_bib18","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.6061\/clinics\/2013(09)03_bib19","first-page":"151","article-title":"Atualiza\u00e7\u00e3o do consenso brasileiro no diagn\u00f3stico e tratamento da artrite reumat\u00f3ide","volume":"47","author":"B\u00e9rtolo","year":"2007","journal-title":"Rev Bras Reumatol"},{"issue":"3","key":"10.6061\/clinics\/2013(09)03_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1590\/S0482-50042007000400001","article-title":"Consenso Brasileiro de Espondiloartropatias: Espondilite Anquilosante e Artrite Psori\u00e1sica Diagn\u00f3stico e Tratamento \u2013 Primeira Revis\u00e3o","volume":"47","author":"Sampaio-Barros","year":"2007","journal-title":"Rev Bras Reumatol"},{"issue":"1","key":"10.6061\/clinics\/2013(09)03_bib21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.6061\/clinics\/2013(09)03_bib22","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"issue":"4","key":"10.6061\/clinics\/2013(09)03_bib23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis-oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"year":"1963","series-title":"Clinical Aspects of immunology","author":"Gell","key":"10.6061\/clinics\/2013(09)03_bib24"},{"issue":"11","key":"10.6061\/clinics\/2013(09)03_bib25","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ncprheum0336","article-title":"Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor","volume":"2","author":"Winthrop","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"4","key":"10.6061\/clinics\/2013(09)03_bib26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.6061\/clinics\/2013(09)03_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MD.0b013e318211106a","article-title":"TNF-\u03b1 Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid Arthritis","volume":"90","author":"Lane","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.6061\/clinics\/2013(09)03_bib28","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1186\/ar3453","article-title":"The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses","volume":"13","author":"Dixon","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.6061\/clinics\/2013(09)03_bib29","first-page":"333","article-title":"Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis","volume":"27","author":"Benucci","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.6061\/clinics\/2013(09)03_bib30","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.6061\/clinics\/2013(09)03_bib31","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/ard.2007.082842","article-title":"Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum","volume":"67","author":"Carter","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.6061\/clinics\/2013(09)03_bib32","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2006.059261","article-title":"A medical conundrum: onset of psoriasis in patients receiving anti-tumor necrosis factor agents","volume":"65","author":"Ritchlin","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.6061\/clinics\/2013(09)03_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alfa therapy: results from the British Society for Rheumatology Biologics Register","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.6061\/clinics\/2013(09)03_bib34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12016-011-8262-2","article-title":"Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis","volume":"42","author":"Pontikaki","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"issue":"Suppl 2","key":"10.6061\/clinics\/2013(09)03_bib35","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1136\/ard.2004.031120","article-title":"Psoriasis pathophysiology: current concepts of pathogenesis","volume":"64","author":"Krueger","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.6061\/clinics\/2013(09)03_bib36","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/rheumatology\/keh437","article-title":"Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-inhibitors","volume":"44","author":"Aeberli","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.6061\/clinics\/2013(09)03_bib37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/RHU.0b013e318190dd88","article-title":"Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha","volume":"14","author":"Cuchacovich","year":"2008","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"10.6061\/clinics\/2013(09)03_bib38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","article-title":"New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor a antagonists","volume":"65","author":"Kary","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.6061\/clinics\/2013(09)03_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaad.2005.02.034","article-title":"Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjects","volume":"53","author":"Tomi","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.6061\/clinics\/2013(09)03_bib40","doi-asserted-by":"crossref","first-page":"R535","DOI":"10.1186\/ar1440","article-title":"Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study","volume":"6","author":"Ferraro-Peyret","year":"2004","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.6061\/clinics\/2013(09)03_bib41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","article-title":"Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF\u03b1","volume":"64","author":"Eriksson","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.6061\/clinics\/2013(09)03_bib42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.semarthrit.2007.08.003","article-title":"Drug-induced lupus due to anti-tumor necrosis factor \u03b1 agents","volume":"37","author":"Costa","year":"2008","journal-title":"Semin Arthritis Rheum"},{"issue":"9306","key":"10.6061\/clinics\/2013(09)03_bib43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.6061\/clinics\/2013(09)03_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0889-857X(21)00226-X","article-title":"Drug-induced lupus","volume":"20","author":"Yung","year":"1994","journal-title":"Rheum Dis Clin North Am"},{"issue":"7","key":"10.6061\/clinics\/2013(09)03_bib45","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/08916930500285857","article-title":"Drug-induced lupus erythematosus","volume":"38","author":"Sarzi-Puttini","year":"2005","journal-title":"Autoimmunity"},{"issue":"11","key":"10.6061\/clinics\/2013(09)03_bib46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/0961203306070000","article-title":"Drug-induced lupus: an update","volume":"15","author":"Vasoo","year":"2006","journal-title":"Lupus"},{"issue":"9","key":"10.6061\/clinics\/2013(09)03_bib47","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Beenhouwer DO. Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222016209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222016209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/clinics.org.br\/uploads\/artigos\/cln-68-09\/cln-68-09-1189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:05:38Z","timestamp":1761721538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222016209"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_abstract&pid=S1807-59322013000901189&lng=en&nrm=iso","label":"SCIELO"},{"URL":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3782714\/?report=classic","label":"PMC"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1807593222016209"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2013(09)03","relation":{},"ISSN":["1807-5932"],"issn-type":[{"type":"print","value":"1807-5932"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2013(09)03","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}]}}